lyophilised powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
== Treatment and prognosis == The recommended treatment for individuals presenting with localized MFS tumors is radical surgical resection. The resection should include a 2 cm margin of soft tissue surrounding the tumor, with planned resection of the entire area as defined by MRI-detected increased signals on T2-weighted images. This is done to ensure that all tumor tissue is removed in order to avoid the high risks of local recurrences and worsening prognoses. Historically, about 10% of patients treated with radical surgery developed recurrences at the surgical site and a significant number of these patients developed metastatic disease. Consequently, adjuvant radiotherapy has been used to help reduce these recurrences and metastatic transformations. For patients with a limb tumor that cannot be resected (less than 5% of all cases)), limb amputation is the treatment of choice. Recurrent and metastatic MFS first-line treatment has employed two chemotherapy drugs, anthracycline and Ifosfamide, while second-line treatment has employed two other chemotherapy drugs, gemcitabine and paclitaxel. Triple chemotherapy drug treatment (adriamycin, ifosfamide, and dacarbazine) has also been used to treat MFS. However, there are no randomized clinical trials evaluating the efficacy of these or other chemotherapy drugs in the treatment of inoperable or metastatic MFS and none of the uncontrolled studies have demonstrated a benefit in improving the overall survival in MFS.
==== Postmodification of homochiral MOFs ==== Lin and coworkers have shown that the postmodification of MOFs can be achieved to produce enantioselective homochiral MOFs for use as catalysts. The resulting 3D homochiral MOF {[Cd3(L)3Cl6] • 4DMF • 6MeOH • 3H2O} (L=(R)-6,6'-dichloro-2,2'-dihydroxyl-1,1'-binaphthyl-bipyridine) synthesized by Lin was shown to have a similar catalytic efficiency for the diethylzinc addition reaction as compared to the homogeneous analogue when was pretreated by Ti(OiPr)4 to generate the grafted Ti- BINOLate species. The catalytic activity of MOFs can vary depending on the framework structure. Lin and others found that MOFs synthesized from the same materials could have drastically different catalytic activities depending on the framework structure present.
By 1859, Cuba still did not have a Grand Lodge, and to accelerate this work, they contacted one of the most powerful figures of Freemasonry in the United States at the time, and today the most controversial figure in the history of North American Freemasonry, Albert Pike, requesting his guidance and assistance. Pike was at that time the Grand Commander of the Supreme Council of the Southern Jurisdiction of the United States for the Scottish Rite at Charleston, South Carolina.On March 26, 1859, Albert Pike gave his personal authority to the Cuban exile Andrés Cassard to create new offices, degrees, and bodies of the Scottish Rite in Cuba. However, later that year, Albert Pike and Albert Mackey also granted this authority to others in Cuba. Whether Cassard was aware of that is unclear. Four initiates from Fraternidad Lodge No. 387 joined three Cuban Freemasons living in Hudson, New York to formally petition the Grand Lodge of South Carolina to grant authority for a third Lodge. San Andres Lodge No. 93 was chartered in November 17, 1859. On November 27, 1859, the Grand Lodge of South Carolina granted a warrant to merge the three Cuban Lodges into the first Grand Lodge seen in Cuba in almost four decades; the Gran Logia de Colón (English: Grand Lodge of Columbus) at Santiago de Cuba. Under the authority Grand Lodge of Colon, the three Lodges were restructured as Fraternidad Lodge No.1, Prudencia Lodge No. 2, and San Andres Lodge No. 3. Francisco Griñán y Mozo served as the first Grand Master of the Grand Lodge of Colon.
Separate and thoroughly wash red blood cells from a peripherally collected EDTA blood collection tube using centrifugation. Mix washed patient red blood cells, that are positive for the IgG phase of the direct antiglobulin test, with glycine acid (pH 3.0). Centrifuge the mixture, and immediately remove the supernatant from the destroyed red blood cells. Add buffer to return the mixture to a neutral pH. This step is critical for further antibody identification testing, because the antibody will not react at a pH of less than 7.0. Additional centrifugation may be needed to clarify the solution. The resulting solution is known as the eluate. This eluate is then tested against a panel of red blood cells with known antigen profiles. This antibody identification procedure will aid in determining the specificity of the antibody.
Sources: en.wikipedia.org
== Further reading == Farlow, J. O.; Gatesy, S. M.; Holtz, T. R. Jr.; Hutchinson, J. R.; Robinson, J. M. (2000). "Theropod Locomotion". American Zoologist. 40 (4): 640–663. doi:10.1093/icb/40.4.640. JSTOR 3884284.
Pseudothrombocytopenia (PTCP) or spurious thrombocytopenia is an in-vitro sampling problem which may mislead the diagnosis towards the more critical condition of thrombocytopenia. The phenomenon may occur when the anticoagulant used while testing the blood sample causes clumping of platelets which mimics a low platelet count. The phenomenon has first been reported in 1969.
On 18 March 2021, German regional leaders including State Premiers and the mayor of Berlin called for the swift approval of the Russian vaccine by the European Medicines Agency to counteract the acute shortages of effective vaccines in Europe. German medical experts have recommended its approval also, and consider the Sputnik Vaccine "clever" and "highly safe". On 19 March 2021, the Philippine Food and Drug Administration granted emergency use authorization for Sputnik V, the fourth COVID-19 vaccine to be given authorization. The Philippine government planned to buy 20 million doses of the vaccine. On 12 April 2021, India approved the use of Sputnik V vaccine for emergency use against COVID-19 based on strong immunogenicity data. As of 12 April 2021, 62 countries had granted Sputnik V emergency use authorization. On 27 April 2021, Bangladesh approved the use of Sputnik V vaccine for emergency use. On 30 April 2021, Turkey and Albania approved the use of Sputnik V vaccine for emergency use.
Sources: en.wikipedia.org
== Side effects == Adverse effects by incidence: Note: Serious (that is, those that can either result in permanent injury or are irreversible or are potentially life-threatening) are written in bold text. Very common (>10% incidence) adverse effects include:
== Medical uses == Topical hydrocortisone is indicated for relieving swelling, irritation and redness in a number of skin conditions, including insect bites, heat rash, eczema, psoriasis, contact dermatitis and nappy rash. It could be formulated as a single active ingredient in some medications, e.g. Cortaid, which is applied for anal itchiness. On some occasions, this drug may be used in combination with other types of drugs to alleviate skin problems. For example, it could be used together with antibiotics such as polymyxin, neomycin and bacitracin to improve dermal conditions.
Beta decay can be considered as a perturbation as described in quantum mechanics, and thus Fermi's Golden Rule can be applied. This leads to an expression for the kinetic energy spectrum N(T) of emitted betas as follows:
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.